TrialClinical cancer research : an official journal of the American Association for Cancer Research2014

The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer.

Alison Backen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.